Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ETCompany ParticipantsEmma Walmsley - Chief ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...